Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Finance

Building on discovery platform and early deals, CBC-backed NiKang adds $200M in crossover series C round

With backing from high-profile crossover investors, four-year-old company taking wholly-owned HIF2A program into clinic

May 26, 2021 10:26 PM UTC

Crossover firms led by Bihua Chen’s Cormorant, Swiss investor HBM and Ting Jia’s Octagon have invested in a $200 million series C round for four-year-old NiKang, a start-up incubated by CBC Group that aims to turn insights into structural biology into small-molecule therapeutics for oncology.

NiKang Therapeutics Inc.’s program targeting HIF2A has yet to reach the clinic, but could deliver first-in-human data by early next year, according to a source with knowledge of the company who did not wish to be identified. The small molecule is NiKang’s most advanced wholly-owned program, although the biotech has out-licensed another to Erasca Inc. and is collaborating on a third with Hansoh Pharmaceutical Group Co. Ltd. (HKEX:0392)...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article